- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Second Price Monitoring Extn
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Second Price Monitoring Extn
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Second Price Monitoring Extn
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Second Price Monitoring Extn
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Lynparza granted orphan drug designation in Japan
AnnouncementREG - AstraZeneca PLC - Imfinzi confirmed overall survival in CASPIAN
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Update on Phase III GY004 trial for cediranib
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Update on Phase III DANUBE trial in bladder cancer
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
Announcement